// App-Quantinova.ai

P529 : Exposure–response relationship of vedolizumab subcutaneous treatment in patients with ulcerative colitis: VISIBLE 1

Researchers

Presenter

  • M Rosario

Principal Investigators

  • D Polhamus

  • N Dirks

  • R Lock

  • X Yao

  • J Chen

  • C Chen

  • W Sun

  • B Feagan

  • W Sandborn

  • G DHaens

Medical Centers

  • Takeda Development Center Americas Inc., Cambridge, USA

  • Metrum Research Group,Tariffville, CT,USA

  • Aucuba Sciences, Ltd.,, Canterbury, Kent, UK

  • Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

  • University of California, San Diego, La Jolla, CA

  • Amsterdam University Medical Center - Amsterdam - Netherlands (The)

Locations

  • United States

  • United Kingdom

  • Canada

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • LDP 02

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT02611830

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved